We recently published a list of Was Jim Cramer Right About These 13 Stocks? In this article, we are going to take a look at ...

Early adopters of GLP-1 drugs have now lost the weight and are beginning to transition off them. How can F&B support the ...

Medications like Ozempic and Mounjaro work by mimicking naturally occurring hormones in the body, such as glucagon-like ...

Many employers are facing challenges in incorporating high-cost GLP-1 medications, such as Mounjaro, Ozempic, Rybelsus, Trulicity, and Wegovy, ...

Mounjaro and Zepbound earned respectively $16.7bn, $8.1bn, $11.5bn and $4.9bn of revenues, representing year-on-year growth of 26%, 86%, 124%, and >2,700% respectively. In short, the GLP-1 agonist ...

Two new class action complaints, both captioned Robins v. Lemme Inc., were filed in in California Superior Court and the Southern District of New ...

Right now, about 12% of American aged 18 or older (or 1 in 8 adults) are taking GLP-1 — glucagon-like peptide-1 — receptor ...

The new move comes as Eli Lilly has also taken action against compounders making copies of tirzepatide, its GLP-1 and GIP agonist sold as Mounjaro for diabetes and Zepbound for obesity in the US.

Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...

Lixisenatide requires daily injections, while newer GLP-1-targeting drugs like Ozempic and Wegovy, as well as Eli Lilly’s tirzepatide-based Mounjaro and Zepbound, only need to be given once a ...